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IS LACK OF MORNING SICKNESS TERATOGENIC? A PRO-
SPECTIVE CONTROLLED STUDY. R. R. Boskovic, MD, The
Hospital for Sick Children, Toronto, Canada.
Introduction: Case control studies have suggested that nausea and
vomiting of pregnancy (NVP) has a protective effect against specific
malformations. These suggestions have been interpreted as if lack of
NVP may put mothers at an increased teratogenic risk.
Objective: To evaluate whether lack of NVP increases the overall
rates for major malformations.
Method: A prospective, cohort controlled study comparing preg-
nancy outcome in women not experiencing NVP with those experi-
encing NVP at two levels of severity. Women who called the Moth-
erisk program about first trimester exposure to drugs but without
NVP were included. The NVP Healthline enrolled two groups of
women with NVP exposed to doxylamine-pyridoxine (DiclectinO` )
for morning sickness. These women were exposed during first tri-
mester of gestation to either higher than standard dose (5-12tbl/day)
or a standard dose (1-4 tbl/day) of Diclectin. The women were
followed up 4-6 months after of the expected date of birth to ascertain
pregnancy outcome.
Results: There were no major malformations among offspring of
130 women not experiencing NVP. There were two major malfor-
mations among 246 women experiencing NVP. The two groups were
of similar distribution of gestational ages, birth rates, as well as rates
of miscarriages and stillbirths.
Conclusions: Lack of NVP does not effect the overall rates of
major malformations. The results of retrospective, case control stud-
ies should not be used to alarm women about such risk.
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CAN SALIVA BE USED FOR THERAPEUTIC DRUG MONI-
TORING OF PROTEASE INHIBITORS IN HIV-INFECTED CHIL-
DREN? N. Y. Rakhmanina, MD, J. N. van den Anker, MD, PhD, J.
Sever, MD, H. Spiegel, MD, PhD, S. L. Soldin, PhD, Children’s
National Medical Center, The George Washington University, Wash-
ington, DC.
Purpose: HIV-infected children may become a target category for
therapeutic drug monitoring (TDM) of antiretroviral therapy (ART)
due to the unpredictability of plasma concentrations. Studies suggest
that saliva could be used instead of blood for TDM. This has distinct
advantages in pediatrics as saliva sampling is painless and prevents
blood loss. The purpose of this study was to determine the total
concentrations of lopinavir and ritonavir in plasma of children with
HIV infection and compare them with the total saliva concentration.
Methods: 15 pediatric patients (median age 8.9 years) receiving
combination ART were enrolled. Unbound lopinavir and ritonavir
were separated by ultrafiltration. The drug serum and saliva concen-
trations were determined by a tandem-mass spectrometric method
using Sciex APT-2000. Routine statistical methods were used to
examine the relation between total drug plasma and saliva concen-
trations.
Results: The relation between total saliva and serum concentra-
tions of lopinavir and ritonavir were highly significant with r values
of 0.991 for ritonavir (RittotalSal  0.043RittotalPl108.7, p0.001)
and 0.993 for lopinavir (LoptotalSal  0.019LoptotalPl-59.26,
p0.0001).
Conclusion: This pilot study demonstrated a significant linear
correlation between total saliva and serum concentrations of lopinavir
and ritonavir. The measurement of concentrations of these drugs in
saliva may be useful for application of TDM of PIs in pediatric
patients.
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PHARMACOKINETICS OF ROFECOXIB IN CHILDREN. D.
J. Edwards, PharmD, R. P. Prescilla, MD, D. A. Fratarelli, MD, D.
Haritos, MD, J. V. Aranda, MD, PhD, Wayne State University,
Children’s Hospital of Michigan, NICHD Pediatric Pharmacology
Research Unit Network, Detroit, MI.
Rofecoxib is a selective COX-2 inhibitor approved for pain control
and the treatment of arthritis in adults. There are no published
pharmacokinetic data in children. We investigated the disposition of
rofecoxib in children with sickle cell hemoglobinopathy admitted for
pain episodes. Subjects (5 males, 3 females) aged 3 to 14 years (mean
8.9 years) with normal liver and kidney function received a single
oral dose of rofecoxib (1 mg/kg, maximum 50 mg) as a suspension.
The mean dose was 35.6 mg (range 15-50 mg). Blood samples were
collected for up to 72 hours following drug administration and plasma
assayed for rofecoxib using HPLC. Peak concentrations of rofecoxib
averaged 582129 ng/mL with a median tmax of 4.0 hours. Two
subjects were discharged at 12 hours and subsequent blood samples
were not obtained preventing characterization of elimination. In the
remaining 6 subjects, oral clearance (Cl/F) averaged 1.320.35 mL/
min/kg with an elimination half-life of 14.84.5 hours. The results
are consistent with studies in adults reporting clearance to be 
120
mL/min with a half-life of 17 hours and suggest that rofecoxib
disposition is similar in children and adults.
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IMMUNOHISTOCHEMICAL LOCALISATION AND MRNA
QUANTIFICATION OF P-GP IN HUMAN TERM PLACENTAS -
NO IMPACT OF CORTICOSTEROID ADMINISTRATION FOR
PRETERM LABOR. R. Serreau, M. Fakhoury, G. Bonihay, Y.
Medard, M. Peuchmaur, A. Mokhdad, J. Oury, E. Jacqz-Aigrain,
Robert Debre Hospital, Jean Rostand Hospital, Paris, France.
P-glycoprotein (P-gp) is an energy-dependent efflux pump ex-
pressed in the syncythiotrophoblast of human placenta throughout
pregnancy, suggesting a potential functional importance of Pgp dur-
ing pregnancy. Human data are limited and the effects of maternal
treatment with corticosteroids in case of preterm labor have not
known.
After maternal consent, placenta from term pregnancies (n20) or
term pregnancies treated with betamethasone for preterm labor
(n43) were studied. Betamethasone (12 mg twice at 24 hour inter-
val) was administered between 22 and 34 week’s gestation, interval
between end of treatment and birth was 35  26 days. Immunohis-
tochemical localisation by a sandwich staining method with Dako
3522 and F4 Kamiya monoclonal antibodies in paraffin embedded
human placenta showned that P-gp is located in the endothelial cells
without evidence for expression in the syncythiotrophoblast. P-gp
mRNA and the constititively expressed mRNA 18S) were measured
by RT-PCR and results expressed as the ratio of Pgp over 18S
mRNA. PgP was highly expressed in the placenta but Pgp/18S
mRNA ratio was not different at term between normal pregnancies
and pregnancies treated with betamethasone. A acute effect of beta-
methasone on P-gp expression cannot be rulled out, as the free
interval between betamethasone and birth was more than three weeks
and will be investigated by additional studies.
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